A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 28 Nov 2024
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Abiraterone acetate; Enzalutamide; Prednisone
- Indications Adenocarcinoma; Pelvic cancer; Prostate cancer; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms CONTACT-02
- Sponsors Exelixis
Most Recent Events
- 15 Sep 2024 According to Ipsen Media Release, company announced detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx (cabozantinib) and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC).
- 15 Sep 2024 Results Presented in the Ipsen Media Release.
- 15 Sep 2024 According to an Exelixis media release, Exelixis intends to submit a supplemental New Drug Application with the U.S. Food and Drug Administration for cabozantinib in combination with atezolizumab for mCRPC later this year.